Latest: FDA Approves New Biosimilar for Oncology Treatment
Healthcare Business

Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC

by American Journal Managed Care
0 Comments
0 Mins
Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Tags:
American Journal Managed Care
Author

American Journal Managed Care

Previous Post
AI Chatbots Easily Misled by False Medical Information, Mount Sinai Study Finds
Next Post
Creating a Seamless Transition from Pediatric to Adult Patient Cancer Care
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago